By further engineering the STING KO cell line with a chimeric non-secretable MSLN receptor for proper MSLN-THV manufacturing, our proof-of-concept study proposes MSLN-THV as potential candidates for preclinical evaluation of breast cancer models [53,54,55]. Here, MSLN is linked to breast carcinoma.